trending Market Intelligence /marketintelligence/en/news-insights/trending/05LtE3a9Ubr9wYS6L-T00w2 content
Log in to other products

Login to Market Intelligence Platform

 /

Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

LexaGene to raise about C$2M to fund pathogen detection platform

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


LexaGene to raise about C$2M to fund pathogen detection platform

LexaGene Holdings Inc. said it plans to raise up to about C$2 million in gross proceeds through a nonbrokered private placement.

The company plans to sell up to 3 million units for 65 Canadian cents apiece, with each unit consisting of one common share and one common share purchase warrant.

Each warrant can be exercised at 85 cents per share for a period of 15 months from the issuance of the units.

LexaGene expects to use the net proceeds from the private placement to develop its LX Analyzer and for related corporate activities including marketing of the technology.

Beverly, Mass.-based LexaGene is a biotechnology company developing an automated pathogen detection platform for veterinary diagnostics, food safety and other markets.